LABELS · e8a259ac-2a09-4026-823c-f23cbcba6a2b

Rituxan Hycela

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-12-15
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WARNING: SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning. Severe mucocutaneous reactions, some with fatal outcomes ( 5.1 ). Hepatitis B virus reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death ( 5.2 ). Progressive multifocal leukoencephalopathy resulting in death ( 5.3 ). Severe Mucocutaneous Reactions Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab-containing products, including RITUXAN HYCELA [see Warnings and Precautions (5.1) ]. Hepatitis B Virus (HBV) Reactivation HBV reactivation can occur in patients treated with rituximab-containing products, including RITUXAN HYCELA, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with RITUXAN HYCELA. Discontinue RITUXAN HYCELA and concomitant medications in the event of HBV reactivation [see Warnings and Precautions (5.2) ] . Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab-containing products, including RITUXAN HYCELA [see Warnings and Precautions (5.3) and Adverse Reactions (6.1) ].

Indications and usage: exact source text

1 INDICATIONS AND USAGE RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1.2 ) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1.3 ) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion. ( 1.4 , 2.1 , 5.4 ). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent. Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. 1.2 Diffuse Large B-Cell Lymphoma (DLBCL) RITUXAN HYCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 1.3 Chronic Lymphocytic Leukemia (CLL) RITUXAN HYCELA is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL. 1.4 Limitations of Use Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion [see Dosage and Administration (2.1) and Warnings and Precautions (5.4) ]. RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions.

Full extracted label fields

application numbers

BLA761064

boxed warning exact

WARNING: SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY WARNING: SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY See full prescribing information for complete boxed warning. Severe mucocutaneous reactions, some with fatal outcomes ( 5.1 ). Hepatitis B virus reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death ( 5.2 ). Progressive multifocal leukoencephalopathy resulting in death ( 5.3 ). Severe Mucocutaneous Reactions Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab-containing products, including RITUXAN HYCELA [see Warnings and Precautions (5.1) ]. Hepatitis B Virus (HBV) Reactivation HBV reactivation can occur in patients treated with rituximab-containing products, including RITUXAN HYCELA, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with RITUXAN HYCELA. Discontinue RITUXAN HYCELA and concomitant medications in the event of HBV reactivation [see Warnings and Precautions (5.2) ] . Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving rituximab-containing products, including RITUXAN HYCELA [see Warnings and Precautions (5.3) and Adverse Reactions (6.1) ].

brand names

Rituxan Hycela

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5b7e82-f018-4eaf-ae78-d6145a906b20

generic names

RITUXIMAB AND HYALURONIDASE

e8a259ac-2a09-4026-823c-f23cbcba6a2b

indications and usage exact

1 INDICATIONS AND USAGE RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1.2 ) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1.3 ) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion. ( 1.4 , 2.1 , 5.4 ). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent. Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. 1.2 Diffuse Large B-Cell Lymphoma (DLBCL) RITUXAN HYCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 1.3 Chronic Lymphocytic Leukemia (CLL) RITUXAN HYCELA is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL. 1.4 Limitations of Use Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion [see Dosage and Administration (2.1) and Warnings and Precautions (5.4) ]. RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions.

indications and usage tables exact

is original packager

true

manufacturer names

Genentech, Inc.

matched search terms

lymphoma
leukemia
malignant

package ndcs

50242-108-01
50242-108-86
50242-109-01

product ndcs

50242-108
50242-109

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Dosage and Administration, Preparation and Administration ( 2.6 ) 06/2021

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

1927885
1927890
1927893
1927894

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1430
end exclusive: true
exact text: 1 INDICATIONS AND USAGE RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1.2 ) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1.3 ) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion. ( 1.4 , 2.1 , 5.4 ). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patient
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 0

current approval status

not_reconciled

duplicate text group

dup-b3605c946f43a8120901

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-029e9e0362b084c296bb

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

end: 160
end exclusive: true
exact text: is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 39

qualifier mentions

context exact
e human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Relapsed or refracto
kind
age
polarity
not_inferred
span
end
196
end exclusive
true
exact text
adult patients
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
182
context exact
S AND USAGE RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for
kind
biomarker
polarity
not_inferred
span
end
104
end exclusive
true
exact text
CD20-directed cytolytic antibody
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
72
context exact
nt of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Relapsed or refractory, follicular lymphoma as a single agent Previously untreated
kind
stage_or_setting
polarity
not_inferred
span
end
258
end exclusive
true
exact text
Relapsed or refractory
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
236
context exact
lapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy Non-progressin
kind
prior_therapy_or_line
polarity
not_inferred
span
end
478
end exclusive
true
exact text
Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chem
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
298
context exact
table disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1.2 ) Previously untreated diffuse large B-cell lymphoma in c
kind
prior_therapy_or_line
polarity
not_inferred
span
end
729
end exclusive
true
exact text
first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
612
context exact
chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1.2 ) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1.3 ) Previously un
kind
prior_therapy_or_line
polarity
not_inferred
span
end
914
end exclusive
true
exact text
Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regim
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
734
context exact
therapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1.3 ) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab pro
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1141
end exclusive
true
exact text
Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after pati
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
961
context exact
ma (FL) ( 1.1 ) Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance t
kind
regimen
polarity
not_inferred
span
end
457
end exclusive
true
exact text
as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
280
context exact
progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1.2 ) Previously untreated diffuse large B-cell lymphoma in c
kind
regimen
polarity
not_inferred
span
end
729
end exclusive
true
exact text
as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
588
context exact
( 1.2 ) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1.3 ) Previously untreated and previously treated CLL in comb
kind
regimen
polarity
not_inferred
span
end
956
end exclusive
true
exact text
in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
785
context exact
LL) ( 1.3 ) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion.
kind
regimen
polarity
not_inferred
span
end
1188
end exclusive
true
exact text
in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1009

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 1230
end exclusive: true
exact text: 1 INDICATIONS AND USAGE RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy Diffuse Large B-cell Lymphoma (DLBCL) ( 1.2 ) Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens Chronic Lymphocytic Leukemia (CLL) ( 1.3 ) Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · unclassified context

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1451
end exclusive: true
exact text: udarabine and cyclophosphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion. ( 1.4 , 2.1 , 5.4 ). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or r
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1031

current approval status

not_reconciled

duplicate text group

dup-beffb6dda43ff90a69d4

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-ee0ee6f9ada201671ae1

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 1251
end exclusive: true
exact text: ( 1.4 , 2.1 , 5.4 ).
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1231

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · limitation of use

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1530
end exclusive: true
exact text: osphamide (FC) Limitations of Use: Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion. ( 1.4 , 2.1 , 5.4 ). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent. Previously untreated follicul
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1052

current approval status

not_reconciled

duplicate text group

dup-2522e476f592aced1e24

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-4c309e2aeab8b7c36e5a

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 1330
end exclusive: true
exact text: RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1252

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · unclassified context

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1538
end exclusive: true
exact text: after patients have received at least one full dose of a rituximab product by intravenous infusion. ( 1.4 , 2.1 , 5.4 ). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent. Previously untreated follicular lymph
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1131

current approval status

not_reconciled

duplicate text group

dup-2346944ac7402591439f

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-e0c9b1a2472209393798

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 1338
end exclusive: true
exact text: ( 1.4 )
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1331

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · positive indication candidate

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1700
end exclusive: true
exact text: tients have received at least one full dose of a rituximab product by intravenous infusion. ( 1.4 , 2.1 , 5.4 ). RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent. Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1139

current approval status

not_reconciled

duplicate text group

dup-c8bde34ed06b70caf28e

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-c51f71bcde0f2a0c584e

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

end: 1395
end exclusive: true
exact text: is indicated
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1383

qualifier mentions

context exact
phoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a sing
kind
age
polarity
not_inferred
span
end
1431
end exclusive
true
exact text
adult patients
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1417
context exact
CELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent.
kind
stage_or_setting
polarity
not_inferred
span
end
1460
end exclusive
true
exact text
Relapsed or refractory
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1438
context exact
patients with: Relapsed or refractory, follicular lymphoma as a single agent.
kind
regimen
polarity
not_inferred
span
end
1499
end exclusive
true
exact text
as a single agent
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1482

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 1500
end exclusive: true
exact text: 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1339

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · positive indication candidate

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1927
end exclusive: true
exact text: of non-malignant conditions. ( 1.4 ) 1.1 Follicular Lymphoma (FL) RITUXAN HYCELA is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma as a single agent. Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. 1.2 Diffuse Large B-Cell Lymphoma
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1301

current approval status

not_reconciled

duplicate text group

dup-3ce1d41c2a4b2a80dff2

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-dfba0aaa589342d9694b

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

end: 1395
end exclusive: true
exact text: is indicated
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1383

qualifier mentions

context exact
Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1681
end exclusive
true
exact text
Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chem
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1501
context exact
Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy.
kind
regimen
polarity
not_inferred
span
end
1721
end exclusive
true
exact text
in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance th
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1542

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 1727
end exclusive: true
exact text: Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1501

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · unclassified context

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2092
end exclusive: true
exact text: ular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. 1.2 Diffuse Large B-Cell Lymphoma (DLBCL) RITUXAN HYCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide,
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1528

current approval status

not_reconciled

duplicate text group

dup-bbcd21d1bacf7cc43971

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-f3e32238bd953b6ec3c9

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

Source null

qualifier mentions

context exact
table disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1891
end exclusive
true
exact text
first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1816
context exact
progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
kind
regimen
polarity
not_inferred
span
end
1891
end exclusive
true
exact text
as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1792

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 1892
end exclusive: true
exact text: Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1728

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2388
end exclusive: true
exact text: single-agent maintenance therapy. Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. 1.2 Diffuse Large B-Cell Lymphoma (DLBCL) RITUXAN HYCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 1.3 Chronic Lymphocytic Leukemia (CLL) RITUXAN HYCELA is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previo
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1693

current approval status

not_reconciled

duplicate text group

dup-ae39ee3206e5dcc83c8c

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-4b40b3c8e51c744a584c

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

end: 1962
end exclusive: true
exact text: is indicated
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1950

qualifier mentions

context exact
ma (DLBCL) RITUXAN HYCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in
kind
age
polarity
not_inferred
span
end
1998
end exclusive
true
exact text
adult patients
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
1984
context exact
YCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
2184
end exclusive
true
exact text
previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regim
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
2004
context exact
nts with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
kind
regimen
polarity
not_inferred
span
end
2187
end exclusive
true
exact text
in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
2055

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 2188
end exclusive: true
exact text: 1.2 Diffuse Large B-Cell Lymphoma (DLBCL) RITUXAN HYCELA is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1893

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · positive indication candidate

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2605
end exclusive: true
exact text: patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 1.3 Chronic Lymphocytic Leukemia (CLL) RITUXAN HYCELA is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL. 1.4 Limitations of Use Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion [see Dosage and Administration (2
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 1989

current approval status

not_reconciled

duplicate text group

dup-5d6d4b0288a79a72e2c3

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-92fbdc5350662fcfdf99

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

end: 2255
end exclusive: true
exact text: is indicated
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 2243

qualifier mentions

context exact
fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL.
kind
age
polarity
not_inferred
span
end
2351
end exclusive
true
exact text
adult patients
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
2337
context exact
ophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
2404
end exclusive
true
exact text
previously untreated and previously treated CLL
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
2357
context exact
nic Lymphocytic Leukemia (CLL) RITUXAN HYCELA is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL.
kind
regimen
polarity
not_inferred
span
end
2404
end exclusive
true
exact text
in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
2257

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 2405
end exclusive: true
exact text: 1.3 Chronic Lymphocytic Leukemia (CLL) RITUXAN HYCELA is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 2189

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 10 · risk or warning

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2725
end exclusive: true
exact text: ocytic Leukemia (CLL) RITUXAN HYCELA is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of adult patients with previously untreated and previously treated CLL. 1.4 Limitations of Use Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion [see Dosage and Administration (2.1) and Warnings and Precautions (5.4) ]. RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 2206

current approval status

not_reconciled

duplicate text group

dup-596433dd8da2ffec2bef

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-8f988f9fd7c22352ce53

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 2646
end exclusive: true
exact text: 1.4 Limitations of Use Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion [see Dosage and Administration (2.1) and Warnings and Precautions (5.4) ].
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 2406

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · limitation of use

application numbers

BLA761064

brand names

Rituxan Hycela

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2725
end exclusive: true
exact text: with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion [see Dosage and Administration (2.1) and Warnings and Precautions (5.4) ]. RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 2447

current approval status

not_reconciled

duplicate text group

dup-2522e476f592aced1e24

extraction review status

automated_candidate_pending_source_review

generic names

RITUXIMAB AND HYALURONIDASE

ind-span-6d5d2c03dc21ab39b7bc

label id

e8a259ac-2a09-4026-823c-f23cbcba6a2b

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

abbreviation
FL
definition exact
Follicular Lymphoma
definition span
end
227
end exclusive
true
exact text
Follicular Lymphoma (FL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
203
abbreviation
DLBCL
definition exact
Diffuse Large B-cell Lymphoma
definition span
end
725
end exclusive
true
exact text
Diffuse Large B-cell Lymphoma (DLBCL)
label id
e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start
688

source span

end: 2725
end exclusive: true
exact text: RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions.
label id: e8a259ac-2a09-4026-823c-f23cbcba6a2b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f0431d1ab339ffa8b67b1244be495f5e463c1edfd0e62d5d8117428ba71c2004
start: 2647

source url

https://api.fda.gov/drug/label.json?search=id%3A%22e8a259ac-2a09-4026-823c-f23cbcba6a2b%22

spl effective date

2025-12-15

spl set id

3e5b7e82-f018-4eaf-ae78-d6145a906b20

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice